

---

# Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Human Prescription Drugs

## Guidance for Industry

### ***REVISED DRAFT GUIDANCE***

**This guidance document is being distributed for comment purposes only.**

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <http://www.regulations.gov>. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact (CDER) Julie Chronis 301-796-1200, or (CBER) Office of Communications, Outreach and Development at 800-835-4709 or 240-402-7800.

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)  
Center for Biologics Evaluation and Research (CBER)**

**February 2015  
Advertising  
Revision 1**

# Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Human Prescription Drugs

## Guidance for Industry

*Additional copies are available from:*

*Office of Communications, Division of Drug Information  
Center for Drug Evaluation and Research  
Food and Drug Administration  
WO51, Room 2201*

*10903 New Hampshire Ave., Silver Spring, MD 20993-0002*

*Phone: 301-796-3400; Fax: 301-847-8714*

*druginfo@fda.hhs.gov*

<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>  
and

*Office of Communication, Outreach and Development, HFM-40  
Center for Biologics Evaluation and Research  
Food and Drug Administration*

*10903 New Hampshire Ave., Bldg. 71, rm. 3128,*

*Silver Spring, MD 20993-0002*

*Phone: 800-835-4709 or 240-402-7800*

*ocod@fda.hhs.gov*

<http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)  
Center for Biologics Evaluation and Research (CBER)**

**February 2015  
Advertising  
Revision 1**

*Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

**TABLE OF CONTENTS**

<b>I.</b>	<b>INTRODUCTION.....</b>	<b>1</b>
<b>II.</b>	<b>BACKGROUND .....</b>	<b>2</b>
<b>A.</b>	<b>Legal Overview .....</b>	<b>2</b>
<b>B.</b>	<b>Policy Overview.....</b>	<b>4</b>
<b>III.</b>	<b>OPTIONS FOR DISCLOSING RISK INFORMATION IN CONSUMER-DIRECTED PRESCRIPTION DRUG PRINT ADVERTISEMENTS AND PROMOTIONAL LABELING .....</b>	<b>5</b>
<b>A.</b>	<b>Language and Readability .....</b>	<b>5</b>
<b>B.</b>	<b>Content.....</b>	<b>6</b>
<b>C.</b>	<b>Format.....</b>	<b>9</b>
1.	<i>Prescription Drug Facts Box.....</i>	<i>9</i>
2.	<i>Question and Answer.....</i>	<i>10</i>
	<b>REFERENCES.....</b>	<b>11</b>

*Contains Nonbinding Recommendations*

*Draft — Not for Implementation*

**Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Human Prescription Drugs**

**Guidance for Industry<sup>1</sup>**

This revised draft guidance, when finalized, will represent the Food and Drug Administration’s (FDA’s or Agency’s) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

**I. INTRODUCTION**

This revised draft guidance provides recommendations on the disclosure of risk information in prescription drug product advertisements and promotional labeling in print media directed toward consumers with respect to the brief summary requirement and the requirement that adequate directions for use be included with promotional labeling.<sup>2</sup> The recommendations describe an alternative disclosure approach that FDA refers to as a *consumer brief summary*. This revised draft guidance does not focus on the presentation of risk information in the main body of promotional labeling or advertisements and does not apply to promotional materials directed toward health care professionals.

This revised draft guidance responds to stakeholder requests for specific guidance on the disclosure of risk information to consumers and incorporates recent social science research results (Aikin, O’Donoghue, et al. 2011). This revised draft guidance revises the draft guidance entitled *Brief Summary: Disclosing Risk Information in Consumer-Directed Print Advertisements* (issued January 2004).

<sup>1</sup> This guidance has been prepared by the Office of Prescription Drug Promotion (OPDP) in the Center for Drug Evaluation and Research (CDER) in consultation with the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration.

<sup>2</sup> The recommendations of this revised draft guidance also apply to biological products that are approved for marketing under section 351 of the Public Health Service Act (PHS Act). Because each biological product also meets the definition of “drug” under the Federal Food, Drug, and Cosmetic Act (FD&C Act), it is also subject to regulation under provisions of the FD&C Act applicable to drugs, as well as the regulations implementing these provisions, except that a biological product licensed under section 351 of the PHS Act is not required to have an approved new drug application under section 505 of the FD&C Act (21 U.S.C. 355). See PHS Act section 351(j) (42 U.S.C. 262(j)). References to “drugs” in this guidance therefore also include biological products that fall within the definition.

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

34 FDA’s guidance documents, including this revised draft guidance, do not establish legally  
35 enforceable responsibilities. Instead, guidances describe FDA’s current thinking on a topic and  
36 should be viewed only as recommendations, unless specific regulatory or statutory requirements  
37 are cited. The use of the word *should* in Agency guidances means that something is suggested or  
38 recommended, but not required.

39

### **II. BACKGROUND**

40

#### **A. Legal Overview**

41

42  
43  
44 Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), the Agency has responsibility for  
45 regulating the manufacture, sale, and distribution of drugs in the United States. This authority  
46 includes oversight of the labeling of drugs (21 U.S.C. 352(a)) and the advertising of prescription  
47 drugs (21 U.S.C. 352(n)).

48

49 A print advertisement<sup>3</sup> for a prescription drug must contain a true statement of the product’s  
50 established name; quantitative composition; information in brief summary relating to side  
51 effects, contraindications, and effectiveness; and, for published direct-to-consumer  
52 advertisements, a statement encouraging consumers to report negative side effects to FDA (21  
53 U.S.C. 352(n)). FDA implementing regulations provide further clarification on the information  
54 to include in brief summary: “a true statement of information in brief summary relating to side  
55 effects, contraindications ([to] . . . include side effects, warnings, precautions, and  
56 contraindications and include any such information under such headings as cautions, special  
57 considerations, important notes, etc.) and effectiveness” (21 CFR 202.1(e)(1)). This information  
58 “shall disclose each specific side effect and contraindication . . . contained in required, approved,  
59 or permitted labeling for the advertised drug dosage form(s) . . .” (21 CFR 202.1(e)(3)(iii)). For  
60 purposes of this guidance, the requirement under these provisions that an advertisement for a  
61 prescription drug disclose each side effect, warning, precaution, and contraindication from the  
62 labeling will be referred to as the *brief summary requirement*.

63

64 FDA also has responsibility for regulating labeling for prescription drugs, including promotional  
65 labeling. Section 201(m) of the FD&C Act defines *labeling* as “all labels and other written,  
66 printed, or graphic matter (1) upon any article or any of its containers or wrappers, or (2)  
67 accompanying such article” (21 U.S.C. 321(m)).<sup>4</sup> The U.S. Supreme Court has explained that  
68 the language “accompanying such article” in the “labeling” definition is interpreted broadly, to  
69 include materials that supplement or explain an article. No physical attachment between the  
70 materials and the article is necessary; rather, it is the textual relationship between the items that  
71 is significant (*Kordel v. United States*, 335 U.S. 345, 350 (1948)). FDA generally recognizes  
72 two types of labeling for drugs: (1) FDA-required labeling<sup>5</sup> and (2) promotional labeling.

---

<sup>3</sup> The FD&C Act does not define what constitutes an “advertisement,” but FDA regulations provide several examples, including “advertisements in published journals, magazines, other periodicals, and newspapers, and advertisements broadcast through media such as radio, television, and telephone communication systems” (21 CFR 202.1(l)(1)). Broadcast advertisements, such as radio and television advertisements, are not the subject of this guidance.

<sup>4</sup> See also 21 CFR 1.3(a).

<sup>5</sup> Much FDA-required labeling is subject to FDA review and approval. For example, after drafting by the manufacturer, labeling is reviewed and approved by FDA as part of the new drug application (NDA), new animal

## Contains Nonbinding Recommendations

Draft — Not for Implementation

73 Promotional labeling is generally any labeling, other than the FDA-required labeling, that is  
74 devised for promotion of the product. Examples of materials that may be considered  
75 promotional labeling pieces for prescription drugs are described in 21 CFR 202.1(l)(2).  
76

77 While drug labeling generally must bear “adequate directions for use” (21 U.S.C. 352(f)(1),  
78 prescription drugs are exempt from this requirement if certain conditions are met. These  
79 conditions include, among others, that “any labeling” (as defined in section 201(m) of the FD&C  
80 Act) that is “distributed by or on behalf of the manufacturer, packer, or distributor of the drug,  
81 that furnishes or purports to furnish information for use or which prescribes, recommends, or  
82 suggests a dosage for the use of the drug” contains “adequate information for such use” (21 CFR  
83 201.100(d)). “Adequate information for such use” includes, among other things, “relevant  
84 warnings, hazards, contraindications, side effects, and precautions, under which practitioners  
85 licensed by law to administer the drug can use the drug safely and for the purposes for which it is  
86 intended, including all conditions for which it is advertised or represented . . .” (21 CFR  
87 201.100(d)(1)).<sup>6</sup> The regulation also requires that if the article is subject to section 505 of the  
88 FD&C Act, the parts of the labeling providing such information for use are the same “in  
89 language and emphasis” as labeling approved or permitted under the provisions of section 505.  
90 (Id).  
91

92 In addition, in order to be exempt from the “adequate directions for use” requirement in 21  
93 U.S.C. 352(f), any labeling described in 21 CFR 201.100(d) must contain the “information  
94 required, and in the same format specified by” 21 CFR 201.56, 201.57, and 201.80 (21 CFR  
95 201.100(d)(3)). Generally, the requirements in 21 CFR 201.100(d) have been fulfilled by  
96 including the full FDA-approved package insert (PI) with promotional labeling materials. For  
97 purposes of this guidance, the requirement under these provisions that a prescription drug  
98 promotional labeling piece include the information set forth in 21 CFR 201.100(d), which is  
99 generally fulfilled by inclusion of the full PI, will be referred to as the *adequate directions for*  
100 *use requirement*.  
101

102 To fulfill the brief summary requirement, consumer-directed print advertisements for  
103 prescription drugs frequently include the complete risk-related sections of the PI (also known as  
104 the “traditional approach” or “traditional format”). To fulfill the adequate directions for use  
105 requirement for promotional labeling pieces, the full PI has generally been used. As discussed  
106 more fully in section II.B, FDA believes these approaches are not optimal for consumer-directed  
107 prescription drug print advertisements and promotional labeling pieces because many consumers  
108 lack the technical background to understand some of the information as described in the PI.  
109 Additionally, information that may be of limited use to consumers (e.g., clinical pharmacology)  
110 is included. For these reasons, if manufacturers, packers, and distributors, or anyone acting on  
111 their behalf (firms) include the appropriate information discussed in this guidance, FDA does not  
112 intend to object for failure to include each side effect from the PI in the brief summary in

---

drug application (NADA), biologics license application (BLA), or premarket approval application (PMA) review (see 21 CFR 314.50(c)(2), 514.1(b)(3), and 601.2(a)). For a prescription drug to be exempted from the FD&C Act’s requirement of adequate directions for use (21 U.S.C. 352(f)(1)), its FDA-required labeling must contain, among other information, information addressing product hazards and other risk information, as specified in FDA regulations (21 CFR 201.100(d)(1), (3), and 201.105(c)(1)).

<sup>6</sup> “Adequate information for use” under 21 CFR 201.100(d)(1) also includes indications, effects, dosages, routes, methods, and frequency and duration of administration.

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

113 consumer-directed print advertisements. Furthermore, if firms include the appropriate  
114 information discussed in this guidance, FDA does not intend to object for failure to include the  
115 entire PI to fulfill the requirements of 201.100(d) for consumer-directed promotional labeling  
116 pieces.

117  
118 In other words, this revised draft guidance recommends alternative approaches firms may use to  
119 develop content that can be used to fulfill both the brief summary requirement for consumer-  
120 directed prescription drug print advertisements and the requirements in 201.100(d) in consumer-  
121 directed prescription drug print promotional labeling pieces. Suggested research-tested formats  
122 for this information are also provided in this revised draft guidance. The examples included  
123 throughout are intended to provide guidance and illustrate possible approaches; firms may use  
124 alternative approaches if these approaches satisfy the requirements of the statute and regulations.

125

### **B. Policy Overview**

126  
127

128 To provide better and more actionable information for consumers, FDA believes that the brief  
129 summary should focus on the most important risk information rather than an exhaustive list of  
130 risks and that the information should be presented in a way most likely to be understood by  
131 consumers. Thus, FDA strongly recommends against the use of the traditional approach to fulfill  
132 the brief summary requirement in consumer-directed advertisements, an approach in which risk-  
133 related sections of the PI are presented verbatim, often in small font. Because the target audience  
134 of the PI is health care providers, it is written in highly technical medical terminology, which is  
135 potentially of limited value to consumers who may not have the medical or scientific background  
136 to understand this information. In an FDA survey, few respondents reported reading half or  
137 more of the brief summary presented in the traditional format. Of those who read at least some  
138 of the brief summary, 55 percent described it as hard to read. Over 40 percent of respondents in  
139 the survey reported they do not usually read any of the brief summary in direct-to-consumer  
140 prescription drug print advertisements (Aikin, Swasy, et al. 2004).

141

142 Furthermore, the risk information in the PI sometimes includes lengthy lists of all possible  
143 adverse events. In general, FDA believes that exhaustive lists that include even minor risks  
144 detract from, and make it difficult for, consumers to comprehend and retain information about  
145 the more important risks. While remaining an important source of information for consumers,  
146 even the volume of material in excerpted sections of the PI, along with the format (i.e., a smaller  
147 font with limited white space) and the technical language, may serve to detract from consumers'  
148 comprehension of the information or from the likelihood of consumers reading the material in its  
149 entirety. Research has demonstrated that people process only a limited amount of information at  
150 one time both in general communications (Lavie 2001; Miller 1994; Shapiro 2001) and in direct-  
151 to-consumer prescription drug advertising specifically (Stotka, Rotelli, et al. 2007). Past  
152 research has shown that alternative formats for the brief summary outperform the traditional,  
153 non-consumer-friendly brief summary on measures of consumer risk comprehension (Riggs,  
154 Holdsworth, et al. 2004; Schwartz, Woloshin, et al. 2009; Stotka, Rotelli, et al. 2007; Thumma  
155 1997).

156

157 Occasionally, sections taken from the PI to fulfill the brief summary requirement are rewritten in  
158 a manner that is meant to be more understandable to consumers. However, this approach does

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

159 not necessarily solve the problems with the traditional approach. In research conducted by FDA,  
160 participants who viewed the brief summary information in a format similar to the over-the-  
161 counter (OTC) “Drug Facts” box had better risk recall than those who viewed a traditional, but  
162 consumer-friendly, version of the brief summary. Two additional alternative formats (a Question  
163 and Answer (Q&A) format and a Highlights version from the content and format rule of 2006<sup>7</sup>)  
164 did not differ from the consumer-friendly traditional format on risk recall or confidence (Aikin,  
165 O’Donoghue, et al. 2011).<sup>8</sup>  
166

167 For similar reasons that are further exacerbated by the length and complexity of the full approved  
168 professional labeling, FDA also strongly recommends against providing the full PI to satisfy the  
169 adequate directions for use requirement for consumer-directed print promotional labeling pieces  
170 for prescription drugs. While the Agency recognizes that 21 CFR 201.100(d) identifies the PI as  
171 a source for furnishing adequate directions for use, FDA believes that following the content and  
172 format recommendations in this guidance will better communicate information and help  
173 consumers make informed decisions about the medication being promoted. By adopting the  
174 content and format recommendations in this guidance, firms can also provide consumers with the  
175 same information in both advertising and promotional labeling pieces.  
176

### **177 III. OPTIONS FOR DISCLOSING RISK INFORMATION IN CONSUMER- 178 DIRECTED PRESCRIPTION DRUG PRINT ADVERTISEMENTS AND 179 PROMOTIONAL LABELING**

180  
181 FDA does not intend to object if a firm does not include “each specific side effect and  
182 contraindication” from the PI in the brief summary in consumer-directed print advertisements  
183 (21 CFR 202.1(e)(3)(iii)), or does not supply the entire PI to fulfill the requirements in 21 CFR  
184 201.100(d) for consumer-directed print promotional labeling pieces, so long as the firm follows  
185 the recommendations and examples in this guidance. These alternate approaches will not  
186 become a part of FDA-approved labeling.  
187

188 **For purposes of this guidance, in the text and examples below, the consumer-directed**  
189 **document recommended by FDA as an alternative to the full PI or the risk portions of the**  
190 **PI in consumer-directed prescription drug print promotional labeling pieces and the brief**  
191 **summary requirement in consumer-directed prescription drug advertisements will be**  
192 **referred to as the “consumer brief summary.”**  
193

#### **194 A. Language and Readability**

195  
196 FDA strongly encourages the use of consumer-friendly language in all consumer-directed  
197 materials. The consumer brief summary should be written in language designed for  
198 understanding by a broad target audience with various levels of literacy skills. Technical

---

<sup>7</sup> See 21 CFR 201.56, 201.57, 201.58, and 201.80.

<sup>8</sup> Participants who viewed the brief summary information in a format similar to the OTC Drug Facts box had better risk recall, greater confidence in their ability to perform tasks related to the brief summary, more positive attitudes toward the ad, and greater preference for the format than did those who viewed a traditional, but consumer-friendly, version of the brief summary. Participants had more positive attitudes toward the Q&A format and the Highlights format than toward the traditional format, and participants who viewed the Q&A format had more positive attitudes toward the ad than those who viewed the traditional format.

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

199 language, scientific terms, and medical jargon should be avoided. A conversational tone or  
200 language designed to engage the reader may be useful, such as in the following examples.

201

- 202 • “do not use if you have . . .” or “who should not use . . .” rather than  
203 “contraindications”
- 204 • “what is [drug name]” rather than “indication”
- 205 • “drowsiness” not “somnolence”
- 206 • “fainting” not “syncope”

207

208 The information in the consumer brief summary must be presented in a readable format (21  
209 U.S.C. 352(c); 21 CFR 202.1(e)(7)(viii)). Different techniques can be used to assist consumers  
210 with comprehension of information. For example, *signals*,<sup>9</sup> such as headlines and subheadings,  
211 help communicate important information (Loman and Mayer 1983; Meyer 2003; Spyridakis and  
212 Standal 1987). Consumers are influenced by the layout of print information in their ability to  
213 pay attention to and process specific features of a document (Adams and Edworthy 1995;  
214 Brundage, Feldman-Stewart, et al. 2005; Frantz 1993; Morrow, Leirer, et al. 1995; Niemela and  
215 Saariluoma 2003; Wogalter and Vigilante 2003). Font size and type style can affect the  
216 readability of information (Adams and Edworthy 1995; Arditi and Cho 2005; Baker 2006;  
217 Sheedy, Subbaram, et al. 2005; Tantillo and Mathisen 1995; Wogalter and Vigilante 2003).

218

219 Therefore, the consumer brief summary should be presented visually in a manner designed for  
220 ease of use by consumers. Carrying over elements of the main body of the ad (such as logos and  
221 branded colors) may help the reader understand the connection between the consumer brief  
222 summary and the promotional piece. Font size and style should be selected or designed for  
223 readability. Using double spacing between paragraphs and indentations, as opposed to plain  
224 block paragraphs, helps maximize background space (also called *white space*) and improves  
225 readability. Arranging information in text boxes (i.e., paragraphs of information on a similar  
226 topic surrounded by borders) with headings (Hyona and Lorch 2004) and other attention-drawing  
227 symbols (e.g., bullets, capitalization of select words or phrases) may also be useful to consumers.

228

### **B. Content**

229

230  
231 FDA’s current thinking is that the consumer brief summary should provide clinically significant  
232 information on the most serious and the most common risks associated with the product and omit  
233 less pertinent information. FDA recommends that firms look to available standards to determine  
234 which risks should be included. For example, FDA-approved patient labeling and Medication  
235 Guides, if available for the drug at issue, may be an appropriate starting point to determine which  
236 risks should be included in the consumer brief summary and, in fact, may contain the same risk  
237 information that should appear in the consumer brief summary. However, some information in  
238 patient labeling—such as information found in the Directions for Use section—is not necessary  
239 to include in the consumer brief summary. Additionally, information not contained in patient  
240 labeling, such as information about certain relevant drug risks, might need to be added to the  
241 consumer brief summary.

---

<sup>9</sup> “Signaling” has been defined as the use of “writing devices designed to emphasize aspects of a text’s structure or content without altering the information in the text” (Lorch, Lorch, et al. 1993).

## Contains Nonbinding Recommendations

Draft — Not for Implementation

242  
243 Under the final rule for Requirements on the Content and Format of Labeling for Human  
244 Prescription Drug and Biological Products (the “Physician Labeling Rule” or PLR),<sup>10</sup> the  
245 labeling of new and recently approved products<sup>11</sup> must include Highlights of Prescribing  
246 Information (Highlights). FDA believes the criteria used for selecting risk information for the  
247 Highlights section are an appropriate reference for firms to use when determining which risk  
248 information topics to address in the consumer brief summary. See 21 CFR 201.57(a). In  
249 addition, information in the consumer brief summary should be placed in an order similar to  
250 information in the Highlights section (Boxed Warning followed by Contraindications, Warnings  
251 and Precautions, etc.). However, since information in the Highlights section is intended for use  
252 in conjunction with information in the full PI and the full PI is not being provided, generally the  
253 information in the consumer brief summary should be more detailed and provide more material  
254 information than what is contained in the Highlights. Furthermore, although the PLR is not  
255 applicable to all drugs, similar information can be taken from the analogous sections of each  
256 drug’s PI.

257  
258 For each of the formats discussed below, or for alternative formats, information addressing the  
259 following should be included:

- 260
- 261 • Boxed Warning<sup>12</sup>
  - 262 • All Contraindications
  - 263 • Certain information regarding Warnings and Precautions:
    - 264 ○ the most clinically significant information from the Warnings and Precautions
    - 265 section(s) of the PI;
    - 266 ○ information that would affect a decision to prescribe or take a drug;
    - 267 ○ monitoring or laboratory tests that may be needed;
    - 268 ○ special precautions not set forth in other parts of the PI; and
    - 269 ○ measures that can be taken to prevent or mitigate harm.
- 270

271 FDA also recommends that the most frequently<sup>13</sup> occurring Adverse Reactions be included in the  
272 consumer brief summary.<sup>14</sup> If a product has more than one indication, the most common  
273 Adverse Reactions for each indication being promoted should be included, if included in the PI,  
274 rather than pooled results for all indications (which could include indications that are not being  
275 promoted). Adverse Reactions should be listed in the same order as in the PI.

---

<sup>10</sup> Requirements on the Content and Format of Labeling for Human Prescription Drug and Biological Products (71 FR 3922, Jan 24, 2006).

<sup>11</sup> The PLR applies to prescription drugs that were approved after, on, or five years prior to the effective date of the rule, and to older drugs for which certain supplements are submitted (21 CFR 201.56(b)).

<sup>12</sup> Certain recommendations will not apply to all drugs. For example, not all drugs have a Boxed Warning. If a recommendation is not applicable, the information should be omitted.

<sup>13</sup> The list of Adverse Reactions identified as most frequently occurring or most common is usually generated from a table of Adverse Reactions from clinical trials in the approved labeling. Rates of most common Adverse Reactions vary, but should be appropriate to the nature of a drug’s Adverse Reactions profile and the size and composition of the safety database. See the guidance for industry entitled *Labeling for Human Prescription Drug and Biological Products—Implementing the PLR Content and Format Requirements* (Feb 2013), available on the Internet at <http://www.fda.gov/Drugs/default.htm> under Guidances (Drugs).

<sup>14</sup> This recommendation comports with the information required in the Highlights section (21 CFR 201.57(a)(11)), and is also applicable to drugs to which the PLR does not apply.

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

276  
277 Other important Adverse Reactions, such as those that are serious<sup>15</sup> or those that lead to  
278 discontinuation of the drug or dosage adjustment, should be included unless they are repeated  
279 elsewhere in the PI (e.g., risks included in Warnings and Precautions).  
280  
281 Material information regarding any of these risks may also include the severity of the risks, such  
282 as whether they are debilitating, life-threatening, irreversible, or whether stopping the medication  
283 will alleviate or mitigate the risks. If early warning signs of risks are known, consumers should  
284 be given information about these signs and the importance of informing their health care  
285 provider about the signs. Firms may also include information regarding the need for monitoring  
286 or testing during treatment. Other material information may be relevant depending on the drug  
287 and its risk profile.  
288  
289 FDA also believes that the consumer brief summary should include the indication for the use  
290 being promoted, any clinically significant drug interactions,<sup>16</sup> and information regarding topics  
291 or issues consumers should discuss with their health care providers (e.g., other drugs they are  
292 taking or pre-existing conditions). Other types of information may be included if relevant to the  
293 drug or specific indication referred to in the promotion (e.g., that a drug is not indicated for use  
294 for more than 4 weeks for the indication being advertised even if a different indication allows for  
295 a longer use). Information relating to special populations (e.g., children, the elderly, pregnant or  
296 nursing women, people with liver or renal impairment) should be included if they are of  
297 particular concern based on the drug's known or potential safety profile (e.g., not recommended  
298 for use in children based on adverse events; not for use in nursing women due to the potential for  
299 harm to the infant).  
300  
301 In general, certain information found in the PI or in FDA-approved patient labeling can be  
302 excluded from the consumer brief summary. This information might include dosage and  
303 administration, how the drug is supplied, clinical pharmacology, specific directions regarding use  
304 of the drug (such as how to perform an injection or how to use a patch), or how long the drug  
305 takes to work. However, excluding certain information from the consumer brief summary does  
306 not mean that the same information can be omitted from other parts of the promotional piece  
307 (e.g., information that a drug is administered via an injection versus orally might be material  
308 information that is required in the main body of the promotional piece, while detailed  
309 instructions for use may be omitted from the consumer brief summary).  
310  
311 FDA also recommends that, because the risk information in the consumer brief summary is not  
312 comprehensive, the consumer brief summary should include a statement (1) reminding

---

<sup>15</sup> *Serious Adverse Reaction* refers to any reaction occurring at any dose that results in any of the following outcomes: death, a life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability or incapacity, or a congenital anomaly or birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious Adverse Reactions when, based upon appropriate medical judgment, they may jeopardize the patient or subject, and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. See the guidance for industry entitled *Adverse Reactions Section of Labeling for Human Prescription Drug and Biological Products—Content and Format* (Jan 2006).

<sup>16</sup> For example, for a drug with PLR labeling, typically the most clinically significant drug interactions appear in the Contraindications or Warnings and Precautions sections.

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

313 consumers that the information presented is not comprehensive, (2) suggesting that consumers  
314 speak to their health care provider or pharmacist, and (3) containing a toll-free telephone number  
315 or website address (uniform resource locator or URL) where consumers can obtain the FDA-  
316 approved product labeling.<sup>17</sup> For example:

- 317
- 318 • *The risk information provided here is not comprehensive. To learn more, talk*  
319 *about [drug name] with your health care provider or pharmacist. The FDA-*  
320 *approved product labeling can be found at [www.drugnamePI.com](http://www.drugnamePI.com) or 1-800-555-*  
321 *DRUG.*
  - 322
  - 323 • *This information is not comprehensive.*
  - 324 • *How to get more information:*
    - 325 ▪ *Talk to your health care provider or pharmacist*
    - 326 ▪ *Visit [www.drugnamePI.com](http://www.drugnamePI.com) to obtain the FDA-approved product labeling*
    - 327 ▪ *Call 1-800-555-DRUG*
- 328

329 The consumer brief summary may also contain a title such as “Important Facts” or “Summary of  
330 Information about . . .” along with the drug’s name.<sup>18</sup>

331

332 When the PI is revised, the consumer brief summary for the drug must be reviewed and revised  
333 promptly if pertinent information has been changed (21 CFR 314.70(a)(4), 601.12(a)(4)).

### **C. Format**

334

335 Various formats may be used when conveying information in the consumer brief summary.  
336 Although other formats may be acceptable, the following two sections describe recommended  
337 formats that have been tested in research.

#### *1. Prescription Drug Facts Box*

341

342

343 Ever since the labeling rule for OTC human drugs was finalized more than a decade ago,<sup>19</sup> OTC  
344 products have contained a Drug Facts box on each product. For the consumer brief summary, a  
345 layout similar to the OTC Drug Facts box may be familiar to consumers and may offer  
346 advantages over other formats. In a study testing various brief summary formats, the Drug Facts  
347 box format resulted in better recall of the risk information when compared to the traditional  
348 format (which was written in consumer-friendly language). Consumers in the same study who  
349 saw the Drug Facts box also reported that they felt more confident in their ability to use the  
350 information when compared to consumers who saw the traditional format. In addition,  
351 consumers had more positive attitudes toward the Drug Facts box format than toward two other

---

<sup>17</sup> This recommendation is distinct and separate from the “adequate provision” requirement for broadcast advertisements found at 21 CFR 202.1(e)(1). This guidance only covers print advertisements and print promotional labeling and does not apply to broadcast advertisements.

<sup>18</sup> See the revised draft guidance for industry entitled *Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling* (Nov 2013). When final, this guidance will represent the FDA’s current thinking on this topic.

<sup>19</sup> See Food and Drug Administration, Final Rule; Over-The-Counter Human Drugs, Labeling Requirements (64 FR 13254, Mar 17, 1999).

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

352 formats: the traditional format and a format that is structured like the Highlights section of the  
353 PI (Aikin, O’Donoghue, et al. 2011).

354  
355 Under a prescription Drug Facts box format, information could appear within a box similar to the  
356 OTC Drug Facts box. Standardized headings may assist consumers in locating and  
357 comprehending important drug information. For example:

- 358
- 359 • Uses
  - 360 • Do not use if you
  - 361 • Warnings
  - 362 • Ask a health care provider before use if
  - 363 • When using this product you may have
- 364

365 The recommended content for this format is set forth in section III.B above, and the  
366 recommendation to use consumer-friendly language also applies.

### 367 368 2. *Question and Answer*

369  
370 A Question and Answer (Q&A) format simulates a dialogue using personal pronouns, thus  
371 increasing consumer interest in, and comprehension of, the information. The study testing brief  
372 summary formats found that consumers had more positive attitudes toward a Q&A format than  
373 the traditional brief summary (which was written in consumer-friendly language). However, this  
374 study did not find a difference in risk recall or confidence between the Q&A format and the  
375 traditional format. Because consumers preferred the Q&A format and the format did not  
376 decrease risk recall (Aikin, O’Donoghue, et al. 2011), this format is recommended over the  
377 traditional brief summary.

378  
379 Under the Q&A format, information in the consumer brief summary could appear in columns or  
380 a similar layout. Headings would be framed in the form of questions, for example:

- 381
- 382 • What is [drug] used for?
  - 383 • When should I not take [drug]?
  - 384 • What Warnings should I know about [drug]?
  - 385 • What should I tell my health care provider?
  - 386 • What are the side effects of [drug]?
  - 387 • What other medications might interact with [drug]?
- 388

389 The recommended content for this format is set forth in section III.B above, and the  
390 recommendation to use consumer-friendly language also applies.

391

***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

**REFERENCES**

392  
393  
394 Adams, AS and J Edworthy, 1995, Quantifying and Predicting the Effects of Basic Text Display  
395 Variables on the Perceived Urgency of Warning Labels: Tradeoffs Involving Font Size, Border  
396 Weight, and Color, *Ergonomics*, 38:2221-2237.  
397  
398 Aikin, KJ, AC O'Donoghue, J Swasy, and HW Sullivan, 2011, A Randomized Trial of Risk  
399 Information Formats in Direct-to-Consumer Prescription Drug Advertisements, *Medical*  
400 *Decision Making*, 31:23-33.  
401  
402 Aikin, K, J Swasy, and A Braman, 2004, Patient and Physician Attitudes and Behaviors  
403 Associated with DTC Promotion of Prescription Drugs—Summary of FDA Survey Research  
404 Results, Final Report, FDA (accessible at  
405 <http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/DrugMarketingAdvertisi>  
406 [ngandCommunicationsResearch/UCM152860.pdf](http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/DrugMarketingAdvertisi)).  
407  
408 Arditi, A, and J Cho, 2005, Serifs and Font Legibility, *Vision Research*, 45:2926-2933.  
409  
410 Baker, S, 2006, Provision of Effective Information, *British Dental Journal*, 201:100.  
411  
412 Brundage, M, D Feldman-Stewart, A Leis, A Beznak, L Degner, K Velji, et al., 2005,  
413 Communicating Quality of Life Information to Cancer Patients: A Study of Six Presentation  
414 Formats, *Journal of Clinical Oncology*, 23:6949-6956.  
415  
416 FDA guidance for industry, 2013, Product Name Placement, Size, and Prominence in  
417 Advertising and Promotional Labeling (accessible at  
418 <http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070076.pdf>).  
419  
420 Frantz, JP, 1993, Effect of Location and Presentation Format on Attention to and Compliance  
421 with Product Warnings and Instructions, *Journal of Safety Research*, 24:131-154.  
422  
423 Hyona, J, and RF Lorch, 2004, Effects of Topic Headings on Text Processing: Evidence from  
424 Adult Readers' Eye Fixation Patters, *Learning and Instruction*, 14:131-152.  
425  
426 Lavie, N, 2001, Capacity Limits in Selective Attention: Behavioral Evidence and Implications  
427 for Neural Activity, J Braun, C Koch, and J Davis, eds. *Visual Attention and Cortical Circuits*,  
428 Cambridge, MA: The MIT Press, 49-68.  
429  
430 Loman, NL, and RE Mayer, 1983, Signaling Techniques that Increase the Understandability of  
431 Expository Prose, *Journal of Educational Psychology*, 75:402-412.  
432  
433 Lorch, RF, EP Lorch, and WE Inman, 1993, Effects of Signaling Structure on Text Recall,  
434 *Journal of Educational Psychology*, 85:281-290.  
435  
436 Meyer, BJB, 2003, Text Coherence and Readability, *Topics in Language Disorders*, 23:204-224.  
437

## ***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

- 438 Miller, GA, 1994, The Magical Number Seven, Plus or Minus Two: Some Limits on Our  
439 Capacity for Processing Information, H Gutfreund and G Toulouse, eds. Reprinted in *Biology*  
440 *and Computation: A Physicist's Choice*, River Edge, NJ: World Scientific Publishing Co., 207-  
441 233.
- 442
- 443 Morrow, D, V Leirer, and P Altieri, 1995, List Formats Improve Medication Instructions for  
444 Older Adults, *Educational Gerontology*, 21:151-166.
- 445
- 446 Niemela, M, and P Saariluoma, 2003, Layout Attributes and Recall, *Behaviour and Information*  
447 *Technology*, 22:353-363.
- 448
- 449 Riggs, DL, SM Holdsworth, and DR McAvoy, 2004, Direct-to-Consumer Advertising:  
450 Developing Evidence-Based Policy to Improve Retention and Comprehension [Supplementary  
451 Web Exclusive], *Health Affairs*, 23:249-252.
- 452
- 453 Schwartz, LM, S Woloshin, and HG Welch, 2009, Communicating Drug Benefits and Harms  
454 with a Drug Facts Box: Two Randomized Trials, *Annals of Internal Medicine*, 150:516-527.
- 455
- 456 Shapiro, K, ed., 2001, *The Limits of Attention: Temporal Constraints in Human Information*  
457 *Processing*, London: Oxford University Press.
- 458
- 459 Sheedy, JE, MV Subbaram, AB Zimmerman, and JR Hayes, 2005, Text Legibility and the Letter  
460 Superiority Effect, *Human Factors*, 47:797-815.
- 461
- 462 Spyridakis, JH, and TC Standal, 1987, Signals in Expository Prose: Effects on Reading  
463 Comprehension, *Reading Research Quarterly*, 22:285-298.
- 464
- 465 Stotka, JL, MD Rotelli, SA Dowsett, MW Elsner, SM Holdsworth, PJ Pitts, and DR McAvoy,  
466 2007, A New Model for Communicating Risk Information in Direct-to-Consumer Print  
467 Advertisements, *Drug Information Journal*, 41:111-127.
- 468
- 469 Tantillo, J, J Di Lorenzo-Aiss, and RE Mathisen, 1995, Quantifying Perceived Differences in  
470 Type Styles: An Exploratory Study, *Psychology and Marketing*, 12:447-457.
- 471
- 472 Thumma, C, May 1997, Consumer Engagement with Health Information, Paper Presented at the  
473 Meeting of the Marketing and Public Policy Conference, Washington, DC.
- 474
- 475 Wogalter, MS, and WJ Vigilante, 2003, Effects of Label Format on Knowledge Acquisition and  
476 Perceived Readability by Younger and Older Adults, *Ergonomics*, 46:327-344.